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The aim of this study was to determine the impact of carbapenemase-producing Enterobacteriaceae (CPE) in Spain in 2013 by
describing the prevalence, dissemination, and geographic distribution of CPE clones, and their population structure and antibi-
otic susceptibility. From February 2013 toMay 2013, 83 hospitals (about 40,000 hospital beds) prospectively collected nondupli-
cate Enterobacteriaceae using the screening cutoff recommended by EUCAST. Carbapenemase characterization was performed
by phenotypic methods and confirmed by PCR and sequencing. Multilocus sequencing types (MLST) were determined for Kleb-
siella pneumoniae and Escherichia coli. A total of 702 Enterobacteriaceae isolates met the inclusion criteria; 379 (54%) were CPE.
OXA-48 (71.5%) and VIM-1 (25.3%) were the most frequent carbapenemases, and K. pneumoniae (74.4%), Enterobacter cloacae
(10.3%), and E. coli (8.4%) were the species most affected. Susceptibility to colistin, amikacin, and meropenem was 95.5%,
81.3%, and 74.7%, respectively. The most prevalent sequence types (STs) were ST11 and ST405 for K. pneumoniae and ST131 for
E. coli. Forty-five (54.1%) of the hospitals had at least one CPE case. For K. pneumoniae, ST11/OXA-48, ST15/OXA-48, ST405/
OXA-48, and ST11/VIM-1 were detected in two or more Spanish provinces. ST11 isolates carried four carbapenemases (VIM-1,
OXA-48, KPC-2, and OXA-245), but ST405 isolates carried OXA-48 only. A wide interregional spread of CPE in Spain was ob-
served, mainly due to a few successful clones of OXA-48-producing K. pneumoniae (e.g., ST11 and ST405). The dissemination of
OXA-48-producing E. coli is a new finding of public health concern. According to the susceptibilities determined in vitro, most
of the CPE (94.5%) had three or more options for antibiotic treatment.
Carbapenemase-producing Enterobacteriaceae (CPE), mainlyKlebsiella pneumoniae, are an emerging threat to public and
individual health worldwide. These microorganisms are often re-
sistant to almost all available antibiotics (1, 2), so there are few
alternative treatment options. The most common carbapen-
emases are KPC (class A); VIM, IMP, and NDM (class B); and the
OXA-48 types (class D). However, the extent to which health care
systems have been affected and the carbapenemase types that are
predominant differ substantially from country to country (3).
A multicenter study performed in Spain in 2009 revealed 43
(0.04%) cases of CPE, which were mostly VIM-1 and IMP-22 (4).
After that, we reported a rapid increase in the number of cases of
CPE, mainly OXA-48-producing K. pneumoniae, in this country
from 2010 to 2012 (5–7).
Because previous studies (5, 6) were based on voluntary reports
without taking into account key important issues, in this paper, we
present data on the impact of CPE as obtained from a prospective,
multicenter, and population-based study. We show that carbap-
enemase production in this country is widely and irregularly dis-
tributed; however, the rates of susceptibility to meropenem and
colistin were still high.
(The preliminary results of this study were presented in part at
the 24th European Congress of Clinical Microbiology and Infec-
tious Diseases Annual Meeting, 10 to 13 May 2014 in Barcelona,
Spain, abstract eP-953 [8]).
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MATERIALS AND METHODS
Study design and bacterial isolates. A prospective multicenter study was
designed to identifyEnterobacteriaceae isolates with decreased susceptibil-
ity to carbapenems. The isolates were collected from clinical infections
and carriers between February and May 2013. Eighty-three Spanish hos-
pitals from 33 out of the 50 Spanish provinces participated in the study;
these 33 provinces belonged to 15 of the 17 Spanish Autonomous Com-
munities. Eight of the hospitals acted as coordinating centers. The esti-
mated catchment population was approximately one-half of the Spanish
population and consisted of approximately 21.7 million individuals and
40,100 hospital beds. The participating hospitals registered the total num-
ber of infections caused by Enterobacteriaceae during the study period so
that the values for CPE prevalence could be estimated; the presence of
infections was established according to previously defined criteria (9).
EUCAST screening cutoff values were used to identify CPE (10). The
inclusion criteria were all Enterobacteriaceae isolates presenting either
MICs of 0.125 mg/liter to meropenem and/or ertapenem and/or 1
mg/liter to imipenem, or disk inhibition zones obtained using the disk
diffusion method of 25 mm to meropenem and/or ertapenem and/or
23 mm to imipenem. Only one isolate per patient and species was con-
sidered for further analysis. Isolates from the genera Proteus, Providencia,
and Morganella that had reduced susceptibility to imipenem but were
susceptible to ertapenem and meropenem were not included in the anal-
ysis; in addition, Enterobacter isolates that had reduced susceptibility to
ertapenem but were susceptible to imipenem and meropenem were ex-
cluded.
Bacterial identification and drug susceptibility testing. The initial
assays on the isolates were performed at each participating hospital using
standard microbiological methods. Each hospital also submitted their iso-
lates to one of the eight coordinating centers, where carbapenemase pro-
duction was confirmed using phenotypic and genotypic methods. Finally,
all study isolates were submitted to the antibiotic laboratory of the Span-
ish National Centre of Microbiology, which acted as a central reference
laboratory. All isolates meeting the phenotype inclusion criteria (10) were
classified using the algorithm for phenotypic carbapenemase detection
recommended by EUCAST (10). A modified Hodge test using a mero-
penem disk with cloxacillin (600 g) was performed on all isolates. In
addition, the degree of inhibition of carbapenemase activity was deter-
mined by comparing the inhibition zones obtained from meropenem
disks with or without EDTA (10 l of a 0.5 M solution), phenylboronic
acid (400 g), and cloxacillin (600 g) in all isolates. The Carba NP
method was used as a confirmatory test of carbapenemase activity when
unclear phenotypic results or discrepancies between the phenotypic and
genotypic results were observed (11).
Antibiotic susceptibility testing was performed using the disk diffu-
sion and microdilution susceptibility methods, according to EUCAST
guidelines (12, 13); in addition, susceptibility to ertapenem, imipenem,
meropenem, and colistin was determined by a gradient test (bioMérieux,
Marcy-l’Étoile, France).
Extended-spectrum -lactamase (ESBL) production in OXA-48 and
class B carbapenemase producers was suspected if activity of cefotaxime
and aztreonam, respectively, was recovered in the presence of clavulanic
acid. In the case of KPC producers, the molecular characterization of
ESBL genes was carried out in all isolates.
Characterization of resistance mechanisms. The presence of genes
encoding carbapenemases (blaOXA-48, blaKPC, blaVIM, blaIMP, and
blaNDM) (5) and ESBLs (blaTEM, blaSHV, and blaCTX-M) (14) was deter-
mined using PCR and DNA sequencing assays.
Molecular epidemiology. Multilocus sequence typing (MLST) was
performed for all carbapenemase-producingK. pneumoniae isolates using
the Institut Pasteur scheme (http://www.pasteur.fr/recherche/genopole
/PF8/mlst/Kpneumoniae.html). Carbapenemase-producing Escherichia
coli isolates were typed by MLST using the University of Warwick (War-
wick Medical School, Coventry, United Kingdom) scheme (http://mlst
.warwick.ac.uk). The phylogenetic relationships among the different se-
quence types (STs) found in this study were established according to the
eBURST program version 3 (http://eburst.mlst.net).
A simple diversity index (SDI) previously described by Gastmeier et al.
(15) was applied to analyze the population diversity, calculated as (num-
ber of STs/total number of isolates) 100.
We considered that two or more isolates of K. pneumoniae or E. coli
(including clinical cases and carriers) were epidemiologically related if
they belonged to the same species, had the same MLST, and produced the
same carbapenemase type. For Enterobacter cloacae, this epidemiological
association was established when the genetic linkage was 85% using
pulsed-field gel electrophoresis (PFGE) after total chromosomal DNA
digestion with XbaI (14).
Statistical analysis. Differences in the prevalence values for resistance
mechanisms between the different groups were assessed using Fisher’s
exact test. Associations were determined by calculating odds ratios (ORs)
with their 95% confidence intervals (CIs). The null hypothesis was re-
jected for P values of 0.05. Statistical analysis was performed using the
GraphPad Prism software, version 3.02 (GraphPad Software, Inc., San
Diego, CA, USA).
RESULTS AND DISCUSSION
Bacterial isolates and carbapenemase types. A total of 702 Enter-
obacteriaceae isolates that were collected from an equal number of
patients met the phenotypic criteria for inclusion, with K. pneu-
moniae (53.3%), E. cloacae (15.8%), and E. coli (13.8%) being the
most common species (Table 1). Of these 702 isolates, 379 (54%)
were confirmed to be CPE and were distributed as follows: 282
(74.4%) were K. pneumoniae, 39 (10.3%) were E. cloacae, 32
(8.4%) were E. coli, 11 (2.9%) were Klebsiella oxytoca, 7 (1.8%)
were Citrobacter freundii, 4 (1.1%) were Serratia marcescens, 2
(0.5%) wereEnterobacter aerogenes, 1 (0.3%) wasMorganellamor-
ganii, and 1 (0.3%) was an Enterobacter species (Table 1). The
percentages of CPE isolates significantly varied between species:
75.4% (282 of 374) of the K. pneumoniae, 35.1% (39 of 111) of the
E. cloacae, and 33% (32 of 97) of the E. coli isolates were CPE
isolates; the percentage obtained for K. pneumoniae was signifi-
cantly higher than that for E. cloacae and E. coli (P 0.0001). In a
recent French study, 1485 Enterobacteriaceae isolates that were
nonsusceptible to carbapenems, according the EUCAST criteria,
were detected (42.2% and 35.2% were Enterobacter spp. and K.
pneumoniae, respectively); of them, 340 (22.9%) isolates were car-
bapenemase producers (65.9% and 9.7% were K. pneumoniae and
Enterobacter spp., respectively) (16).
Of the 379 CPE isolates detected, 300 (79.2%) were isolated
from clinical samples and were mostly from urine (158 [52.7%]),
wound (59 [19.7%]), respiratory (37 [12.3%]), and blood (28
[9.3%]) samples. The remaining 79 CPE (20.2%) isolates were
from screening samples (81% from rectal or perianal samples). In
total, 193 CPE cases (50.9%) were isolated from males, and 239
(63.1%) were from patients65 years of age.
The carbapenemase types identified were 271 (71.5%) OXA-48
group (258 OXA-48 and 13 OXA-245), 96 (25.3%) VIM (95
VIM-1 and one VIM-2), 8 (2.1%) KPC-2, and 6 (1.6%) IMP (4
IMP-13 and two IMP-22). Each of the two K. oxytoca isolates
produced both KPC-2 and VIM-1; these two isolates came from
two different hospitals from the Madrid area and were isolated in
March 2013 and May 2013. The isolates from carriers had the
following carbapenemase types: 69.6% OXA-48 group, 30.3%
VIM group, and 1.3% KPC. K. pneumoniae was more prevalent
among the OXA-48 isolates (86.7%) than among the VIM isolates
(44.8%) (P  0.0001). A comparison of OXA-48-group- and
VIM-group-producing isolates is shown in Table 2.
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OXA-48 prevalence is also increasing in other European coun-
tries, such as France, Germany, Belgium, and the United King-
dom, where increasing numbers of outbreaks have been described
(1, 17–21). However, OXA-48 is rarely identified in North Amer-
ica (22). Compared with OXA-48 and VIM, KPC was identified
very infrequently in this study. However, KPC-producing Entero-
bacteriaceae have already caused sporadic hospital outbreaks in
Spain (3, 23). KPC enzymes are endemic in other European coun-
tries, such as Greece and Italy (1, 3, 24), and they produce noso-
comial outbreaks in North America (1). The number of carbap-
enemase-producing E. coli isolates identified in this study was
much higher than that in previous studies (4, 5). This remarkable
finding is of serious concern, because E. coli may facilitate the
community spread of carbapenemases.
ESBL production was detected in 267 of the 379 CPE (70.4%)
isolates; 227 (85%) produced CTX-M-15, 16 (6%) produced SHV-
12, 15 (5.6%) produced CTX-M-9, 9 (3.4%) produced SHV-134, 1
(0.4%) produced CTX-M-14, and 1 (0.4%) produced CTX-M-1.
Two CPE isolates had two different types of ESBLs. Carbapenemase-
producing K. pneumoniae isolates more frequently coproduced
ESBLs (235 of 282 isolates [83.3%]) than did E. cloacae (18 of 38
isolates [47.4%]) or E. coli (11 of 32 isolates [34.4%]) isolates (P
0.0001). The coproduction of ESBLs occurred in 90.6% and 28%
of the OXA-48-producing K. pneumoniae and E. coli isolates, re-
spectively (P 0.0001), mostly of the CTX-M-15 type. Potron et
al. (25) found that the coproduction of OXA-48 and CTX-M-15
occurred in 41.7% of OXA-48-producing E. coli isolates from 10
different European and African countries. Five OXA-48- and
SHV-12-producing K. pneumoniae isolates belonging to ST147
were isolated in Asturias (northern Spain). Associations between
OXA-48 and ESBLs of the SHV type have infrequently been re-
ported (25).
Antibiotic susceptibility testing. Overall, the antibiotics
showing the highest percentages of susceptibility were colistin
(95.5%), amikacin (81.3%), meropenem (74.7%), tigecycline
(71%), and imipenem (67.6%) (Table 3). However, antibiotic sus-
ceptibility significantly varied between the OXA-48-producing
and VIM-producing isolates (Table 3), with the VIM-producing
isolates usually being more resistant.
A total of 182 CPE (48%) isolates were susceptible to colistin,
TABLE 1 Distribution of carbapenemase-producing Enterobacteriaceae
Species
All isolates
(no. [%])
No. (%) of isolates detected
CBP negativea CBP positive OXA-48 group VIM group KPC group IMP group
K. pneumoniae 374 (53.3) 92 (28.5) 282 (74.4) 235 (86.7) 43 (44.8) 3 (37.5) 1(16.7)
E. cloacae 111 (15.8) 72 (22.3) 39 (10.3) 5 (1.8) 29 (30.2) 1 (12.5) 4 (66.6)
E. coli 97 (13.8) 65 (20.1) 32 (8.4) 25 (9.2) 7 (7.3) 0 0
K. oxytoca 16 (2.3) 5 (1.5) 11 (2.9) 1 (0.4) 10 (10.4)b 2 (25)b 0
C. freundii 14 (2) 7 (2.2) 7 (1.8) 2 (0.7) 3 (3.1) 2 (25) 0
S. marcescens 13 (1.8) 9 (2.8) 4 (1.1) 3 (1.1) 1 (1) 0 0
E. aerogenes 34 (4.8) 32 (9.9) 2 (0.5) 0 2 (2.1) 0 0
M. morganii 21 (3) 20 (6.2) 1 (0.3) 0 1 (1) 0 0
Enterobacter spp. 5 (0.7) 4 (1.2) 1 (0.3) 0 0 0 1 (16.7)
Other 17 (2.4) 17 (5.3) 0 0 0 0 0
Total 702 (100) 323 (100) 379 (100) 271 (100) 96 (100) 8 (100) 6 (100)
a CBP, carbapenemase.
b Two isolates produced both KPC and VIM carbapenemases.
TABLE 2 Comparison of OXA-48-group- and VIM-group-producing
isolates
Variable
No. (%) of isolates
producing:
Odds
ratio 95% CIa P value
OXA-48
group
VIM
group
Age65 yr 187 (69) 32 (47.4) 2.47 1.54–3.97 0.0002
K. pneumoniae 235 (86.7) 43 (44.8) 8.05 4.72–13.72 0.0001
ST11 79 (33.6) 4 (9.3) 4.94 1.70–14.31 0.0001
ST405 73 (31.1) 0 39.35 3.39– 648.40 0.0001
ST15 22 (9.4) 15 (34.9) 0.19 0.089–0.41 0.0001
ST326 22 (9.4) 1 (2.3) 4.34 0.57–33.08 0.22
E. coli 25 (9.2) 7 (7.2) 1.31 0.55–3.13 0.67
E. cloacae 5 (1.8) 29 (29.9) 0.044 0.016–0.12 0.0001
K. oxytoca 1 (0.4) 10 (10.3) 0.032 0.004–0.25 0.0001
a CI, confidence interval.
TABLE 3 Susceptibility to antibiotics in carbapenemase-producing
Enterobacteriaceae isolates
Antibiotic
Total
susceptibility
(%) (n 379)
Susceptibility (%) of
indicated isolate
P value
OXA-48-
group
producing
(n 270)
VIM-
group
producing
(n 97)
Colistin 95.5 95.2 95.9 1
Amikacin 81.3 84.8 73.2 0.014
Meropenem 74.7 80 63.9 0.002
Tigecycline 71 72.6 67 0.30
Imipenem 67.6 74.8 49.5 0.0001
Fosfomycin 48 44.8 57.7 0.03
Chloramphenicol 39.6 46.7 23.7 0.0001
Gentamicin 33.2 37.4 22.7 0.008
Aztreonam 20.1 12.2 40.2 0.0001
Tobramycin 16.4 20.7 5.2 0.0002
Trimethoprim-
sulfamethoxazole
16.1 13.7 18.6 0.25
Ciprofloxacin 12.7 9.3 23.7 0.0007
Ceftazidime 9.5 13.3 0 0.0001
Cefotaxime 7.7 10.8 0 0.0001
Ertapenem 7.1 4.1 16.5 0.0002
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amikacin, tigecycline, and carbapenems (imipenem or meropenem);
of them, 107 were also susceptible to fosfomycin. According to pre-
vious clinical experience (2), the use of a carbapenem (meropenem or
imipenem) for the treatment of a CPE with an MIC of8 mg/liter, in
combination with another active agent, seems reasonable; according
to these criteria, we identified 21 highly resistant CPE isolates (5.5%
[12 OXA-48 isolates, 8 VIM-1 isolates, and 1 KPC-2 isolate]) present-
ing only one or two treatment options from which to choose for
clinical purposes, mainly, colistin and carbapenems (n 5) or colis-
tin and tigecycline (n 5).
Geographic distribution and prevalence of infections due to
CPE in Spain.At least one case of CPE was identified at 45 (54.1%)
of the 83 participating hospitals (Fig. 1). These hospitals were
located in 18 of the 33 (54.5%) participating provinces. In 21
(46.7%) of the 45 hospitals with CPE isolates, potential outbreaks
of epidemiologically related CPE isolates were detected, affecting
209 (55.1%) of the 379 CPE isolates included in this study.
Data about the total number of infections caused by Enterobac-
teriaceae during the study period were provided by 75 (90.4%) of
the participating hospitals. A total of 120,808 single infections were
identified by patient and species. The estimated overall prevalence of
infection by carbapenemase-producing K. pneumoniae was 1.7%
(range, 0 to 11.6%; 231/13,842), and 23 (30.7%) hospitals had a
prevalence of1%. For Enterobacter spp. and E. coli, these figures
were 0.5% (range, 0 to 6.4%; 28/5,085) and 0.03% (range, 0 to
0.4%; 28/91,553), respectively. The prevalences of carbapenemase
production in K. pneumoniae and E. coli in a multicenter study
performed in Spain in 2009 were 0.2% and 0.001%, respectively (4).
Although the number of OXA-48-producing isolates was
greater than the number of VIM-producing isolates (271 versus
96, Table 1), the VIM-producing isolates were more widely geo-
graphically distributed. VIM-producing isolates were detected in
16 (40.5%) provinces, and OXA-48-producing isolates were de-
tected in 10 (30.3%) provinces. This finding might be related to
the earlier detection of VIM in Spain that occurred in 2005 (26)
compared with that of OXA-48 in 2009 (27).
Population structure of carbapenemase-producingK. pneu-
moniae and E. coli isolates causing clinical infections. Using
FIG 1 Geographic distribution of carbapenemase types detected during a prospective multicenter study in Spain (February to May 2013).
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MLST, 24 different sequence types (STs) were identified among
the 221 carbapenemase-producing K. pneumoniae isolates impli-
cated in clinical infections (SDI, 10.6; mean, 9.2 isolates per ST;
range, 1 to 66). The most prevalent STs were ST11 (66 isolates
[29.9%]), ST405 (65 isolates [29.4%]), ST15 (28 isolates [12.7%]),
and ST326 (15 isolates [6.8%]). These four STs were found in
78.8% of the carbapenemase-producing K. pneumoniae isolates.
ST405 and ST11 clinical isolates were each isolated in 18 different
isolates. ST11 carried four different types of carbapenemases
(VIM-1, OXA-48, KPC-2, and OXA-245), but ST405 carried
OXA-48 only. Analysis with eBURST provided an overview of the
STs of the Spanish carbapenemase-producing K. pneumoniae iso-
lates from this study compared with those of all K. pneumoniae
isolates from the MLST database. The major STs found are repre-
sented in Fig. 2. Excluding the isolates from this study, ST11 was
the second most frequent ST in the MLST database (103 of 2,405
[4.28%]), and ST405 was uncommon (4 of 2,405 [0.17%]). In this
eBURST analysis, ST405 was shown as a singleton nonrelated to
other classical STs (Fig. 2). These results suggest that K. pneu-
moniae isolates belonging to ST11 and ST405 strongly contribute
to the dissemination of OXA-48-producing Enterobacteriaceae in
Spain. ST11 has been identified as an international high-risk clone
associated with ESBL and carbapenemase production (28, 29), but
ST405 has recently been associated with OXA-48 production in
Spain, Belgium, and France (5, 6, 18, 19).
Among the 27 carbapenemase-producing E. coli isolates impli-
cated in clinical infections, 16 different STs were identified (SDI,
59.3; mean, 1.7 isolates per ST; range, 1 to 7). ST131 (7 isolates
[26%]) and ST156 (3 isolates [11.1%]) were the most prevalent
STs identified. These findings suggest that compared with K.
pneumoniae, carbapenemase-producing E. coli isolates may have a
more diverse and polyclonal population structure, as has been
demonstrated for other resistance mechanisms, like ESBL (30).
The acquisition of carbapenemases by the globally distributed E.
coli ST131 detected in this and other studies (31, 32) is a finding of
serious concern. In a recent study of OXA-48-producing K. pneu-
moniae and E. coli isolates in several European and North African
countries, the most common STs identified were ST101 and ST38,
respectively (25).
Potential interregional spread of CPE strains. One finding
with epidemiological implications was that some of the more
prevalent K. pneumoniae clones carrying carbapenemases were
identified in more than one Spanish province, suggesting that po-
tential interregional spread of these clones may have occurred;
however, dissemination of OXA-48-encoding plasmids between
isolates of the same prevalent ST cannot be excluded. ST405/
OXA-48 was detected in six, ST15/OXA-48 in four, and ST11/
OXA-48 and ST11/VIM-1 in three different Spanish provinces
each. This interregional spread clearly indicates that further prog-
ress has occurred since the “independent hospitals outbreak”
stage described by Cantón et al. (1).
In addition, these carbapenemase genes are carried by plasmids
and, therefore, their spread is probably due to both the clonal
dissemination of a few specific strains and the transmission of
epidemic autotransferred plasmids carrying them (1, 6, 23).
Conclusions. We found that there was a wide geographic dis-
tribution of CPE species and a clear increasing trend in the num-
ber of infections caused by CPE in Spain. Two successful clones of
K. pneumoniae (ST11 and ST405) carried mainly OXA-48, while
ST15 more often carried VIM. Although still infrequent, the de-
tection of a polyclonal dissemination of OXA-48-producingE. coli
has serious implications for public health.
According to in vitro susceptibilities, most of the CPE (94.5%)
had three or more options for antibiotic treatment.
FIG 2 Population snapshot of sequence types (STs) of K. pneumoniae isolates from the multilocus sequence typing (MLST) database and STs of carbapenemase-
producing K. pneumoniae isolates from this study considered together. The most important ST complexes found in this study (ST11, ST405, ST15, and ST 326)
are emphasized. Some STs with single isolates from the MLST database have been excluded from the image for easy viewing. Each ST is represented by a dot, and
lines connect single-locus variants. The size of the dots is related to the number of isolates. Blue dots represent the putative founders, and grey dots represent
putative subgroup founders.
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The spread of CPE in Spain affected 68% of all provinces,
with a potential interregional spread of CPE strains. This finding
also suggests that the public health situation posed by CPE has
worsened in the last few years in Spain.
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